PsyBio Therapeutics (PSYBF)(PSYB:CA) – PsyBio Continues To Report Development Milestones

0 min read

Thursday, October 14, 2021

PsyBio Therapeutics (PSYBF)(PSYB:CA)
PsyBio Continues To Report Development Milestones

PsyBio Therapeutics is developing biosynthetic psychoactive compounds which offer a new paradigm of treatment to reverse the course of mental health issues. Psychoactive medications treat the illness by rewiring the brain through contemplation and a change of perception in combination with psychotherapy vs. Standard of care (SSRI’s, SNRI’s, MAOI’s, NDRI’s, etc…) which just chemically treat symptoms. Working in partnership with Miami University utilizing a proprietary platform technology to biologically synthesize psilocybin and other targeted next generation active compounds in Psilocybe Cubensis and other fungi and plants.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    PsyBio Has Made Significant Progress.  PsyBio is developing psychedelic compounds for psychiatric disorders.  This field has received recent interest due to clinical efficacy data and the large unmet need for new psychiatric medications. In the past several years, cannabis-derived products have received FDA approval, its legal status has changed, and start-up companies have risen to multi-billion dollar valuations. Many companies have entered the field of psychedelics, yet PsyBio is one of the few that is building a pharmaceutical business around them.

    The Company Met A Significant Manufacturing Milestone.  PsyBio has developed proprietary biosysthesis technologies to produce the compounds that are found in psychedelic mushrooms. Its processes avoid the potency and yield variations that result from extracting the compounds from agriculturally produced mushrooms. The company recently announced that it can manufacture psilocybin, now known as its …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 


No comments yet...

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2022 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.